Cetera Investment Advisers Acquires 7,852 Shares of DexCom, Inc. $DXCM

Cetera Investment Advisers increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 6.5% in the first quarter, HoldingsChannel.com reports. The fund owned 128,775 shares of the medical device company’s stock after acquiring an additional 7,852 shares during the period. Cetera Investment Advisers’ holdings in DexCom were worth $8,087,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Reflection Asset Management bought a new position in DexCom in the 4th quarter worth $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom during the 1st quarter valued at about $25,000. MCF Advisors LLC bought a new stake in shares of DexCom during the 4th quarter valued at about $32,000. DV Equities LLC purchased a new position in shares of DexCom during the fourth quarter valued at about $36,000. Finally, Spire Wealth Management increased its position in shares of DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after buying an additional 305 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DXCM. Citigroup restated a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday. Weiss Ratings downgraded DexCom from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Royal Bank Of Canada raised their target price on DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Finally, Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.12.

DexCom Trading Up 12.0%

NASDAQ:DXCM opened at $83.45 on Friday. The firm has a market capitalization of $32.20 billion, a P/E ratio of 32.98, a PEG ratio of 1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a one year low of $54.11 and a one year high of $87.00. The company’s 50-day simple moving average is $73.14 and its 200 day simple moving average is $69.20.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.34%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the firm earned $0.48 earnings per share. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. As a group, analysts forecast that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Insider Activity at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,506 shares of company stock worth $7,205,258 over the last quarter. 0.28% of the stock is currently owned by company insiders.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.